Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders - Bruns, Robert F.; Mitchell, Stephen N.; Wafford, Keith A.; Harper, Alex J.; Shanks, Elaine A.; Carter, Guy; O'Neill, Michael J.; Murray, Tracey K.; Eastwood, Brian J.; Schaus, John M.; Beck, James P.; Hao, Junliang; et al. (Neuropharmacology, 2018)
Keywords: Animals; Antipsychotic Agents - therapeutic use; Blinking - drug effects; Corpus Striatum - drug effects; Corpus Striatum - metabolism; D1 receptor; Disease Models, Animal; Dopamine; Dopamine Agents - therapeutic use; Eye-blink; Isoquinolines - therapeutic use; Levodopa - therapeutic use; Macaca mulatta; Male; Maze Learning - drug effects; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nervous System Diseases - drug therapy; Nervous System Diseases - metabolism; Parkinson's disease; Positive allosteric modulator; Potentiator; Prefrontal Cortex - drug effects; Prefrontal Cortex - metabolism; Psychotic Disorders - drug therapy; Psychotic Disorders - metabolism; Receptors, Dopamine D1 - genetics; Receptors, Dopamine D1 - metabolism; Reserpine - therapeutic use; Sleep - drug effects; Wakefulness - drug effects; Ser; L-DOPA (PubChem CID 6407); tCREB; VTA; Parkinson's disease; pGluR1; tMH; DETQ (PubChem CID 117720272.); CREB; Potentiator; Positive allosteric modulator; SN; DETQ; LMA; Dopamine; D1 receptor; hD1 mouse; SCH39166 (PubChem CID 107930); GluR1; pCREB; tGluR1; tMIAA; Eye-blink; PAM; SKF 82958 (PubChem CID 1255)